sacituzumab

1. 00:10
   ESMO 2026 现场信号

   Proud of @LucaVisani2 and our Florence team presenting this poster on behalf of an international consortium - brand new data on combining sacituzumab govitecan with #radiotherapy i

1. 23:18
   ESMO 2026 现场信号

   Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01. #
2. 18:37
   ESMO 2026 现场信号

   🧬 Can triplet combinations improve outcomes in advanced urothelial cancer? And how do we manage their toxicity? #OAOnTheGo Series
3. 18:30
   ESMO 2026 现场信号

   #ESMO26 Can sacituzumab tirumotecan + pembrolizumab deliver durable responses? Updated phase II results in cisplatin-ineligible, previously untreated advanced/mUC (N=40).
4. 18:10
   ESMO 2026 现场信号

   🚨 In urothelial cancer, the next frontier may be triplets — but efficacy will only matter if we can actually deliver them safely.
5. 17:00
   ESMO 2026 现场信号

   More ADC + IO data at #ESMO26!
6. 16:55
   ESMO 2026 现场信号

   #ESMO26 | Sacituzumab tirumotecan + pembrolizumab in advanced urothelial cancer (Phase II, n=40): ORR 68% | DCR 88% mPFS11.2 months | mOS NRGrade 3–4 TRAEs: 63% Promising activityr
7. 13:00
   ESMO 2026 现场信号

   🧬 Can triplet combinations improve outcomes in advanced urothelial cancer? And how do we manage their toxicity? #OAOnTheGo Series
8. 07:44
   ESMO 2026 现场信号

   🧬 Could combining 2 antibody-drug conjugates with immunotherapy offer a new approach to treatment-naive metastatic urothelial cancer?

1. 23:11
   ESMO 2026 现场信号

   #ESMO26 Can two ADCs + IO push response rates even higher in 1L metastatic urothelial cancer?
2. 20:11
   ESMO 2026 现场信号

   🎯 #ESMO26 moving to advanced UC the TROPHY-U-01 Cohort 7: Study show Excellent ORR (81%) and mPFS 19.3 mo of the Sacituzumab + EV + Zimbe !😊 @OncoAlert @myESMO @urotoday @PGrivasM
3. 20:04
   ESMO 2026 现场信号

   #ESMO26 | TROPHY-U-01 Cohort 7: Sacituzumab govitecan + EV + zimberelimab in advanced urothelial cancer.
4. 17:09
   ESMO 2026 现场信号

   OncoAlert 4Sight Abstracts to be Presented at #ESMO26

1. 12:01
   BioSpace精选

   ESMO 2026：默沙东副总裁称，与科伦博泰合作的sac-TMT ADC处于“恰到好处”区间

   默沙东副总裁称，与科伦博泰合作的sac-TMT采用不可逆连接子，可在血液中保持稳定直至到达肿瘤，释放表现处于其所说的“恰到好处”区间。原文将其与Trodelvy、Datroway的可逆连接子对照，并指出载荷过早释放可能引发贫血和中性粒细胞减少，释放过慢也可能影响其他表达TROP2的组织。

1. 19:55
   中文产业新闻精选

   科伦博泰TROP2 ADC芦康沙妥珠单抗公布TNBC三期最终OS分析，中位OS 14.7个月

   科伦博泰TROP2 ADC芦康沙妥珠单抗（SKB264）在ESMO大会公布2L+晚期三阴性乳腺癌中国III期最终OS分析，随访29.4个月，中位OS 14.7个月对比化疗9.9个月，HR=0.60；调整后线ADC治疗干扰后HR=0.55。

当前热度 60·可比范围峰值 80（10月25日 01:00）·近 24 小时可比范围变化 +220%·当前参与者 12

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。